FDA Allows Early Access to Experimental Pancreatic Cancer Drug

The Food and Drug Administration announced on Friday that it will allow certain patients with serious pancreatic cancer to access a promising investigational drug, daraxonrasib, before it gains full approval. Patients have been eager to try this treatment, which requires taking three pills a day, especially after it recently produced encouraging clinical trial results.

Revolution Medicines, the company behind daraxonrasib, sought authorization for expanded access, a pathway that enables patients to receive unapproved drugs. Prior to this, no one had been eligible to receive the drug outside of clinical trials, which have seen far greater demand than available spaces.

According to the FDA, patients with metastatic pancreatic cancer who have already undergone treatment are eligible for this program, although it’s unclear when they will actually start receiving the drug. Revolution has announced that it plans to provide the medication at no cost to patients who qualify.

Pancreatic Cancer’s Grim Challenges

Pancreatic cancer, linked to a vital gland involved in digestion and blood sugar regulation, is notoriously lethal, often resulting in a quick decline after diagnosis. It is responsible for over 50,000 deaths per year in the U.S., making up about 8 percent of all cancer fatalities.

The treatment options currently available tend to offer limited benefits. Statistics show that only about 3 percent of patients diagnosed with advanced pancreatic cancer survive for five years. Many families have been advocating for daraxonrasib, expressing their urgency given the slow pace of the drug’s regulatory processes. There’s even mention of it being fast-tracked for approval later this year.

“We’re in a situation where Ian could pass away before it hits the market,” said Emily Solari regarding her husband, Ian Spradlin, who has metastatic pancreatic cancer.

Mr. Spradlin, who has undergone multiple treatment lines, expressed a willingness to try daraxonrasib should he have access.

Patients’ Hopes and Expanded Access

“I want to have more time with my kids,” he noted, shedding light on the personal stakes involved in these medical decisions.

Expanded access, or compassionate use, aims to provide a lifeline to patients facing bleak options, bridging the gap between promising clinical results and market availability. Typically, these drugs are provided free of charge by the developing companies.

The FDA sees numerous requests for early access each year, and while many individual patient requests get approved, larger-scale programs like that of daraxonrasib can also be initiated.

Recently, the FDA has faced criticism from patient advocacy groups regarding delays in drug approvals, especially those targeting rare diseases. In response, the agency is working on streamlining reviews for certain drugs.

Last month, Revolution announced groundbreaking results indicating that daraxonrasib significantly improved survival rates in late-stage clinical trials, with subjects living for over 13 months compared to under seven months for traditional chemotherapy treatments.

Future Steps and Ethical Considerations

This study, which included 501 patients who had already undergone at least one line of chemotherapy, reported unheard-of gains in life expectancy for those in the later stages of the disease. Researchers plan to share further findings at an upcoming cancer conference.

Although daraxonrasib has potential side effects like fatigue and nausea, some patients have described minor health issues, such as rashes and split fingertips. Ben Sasse, a well-known participant in the trials, acknowledged that while side effects are present, the treatment has effectively shrunk his tumors.

Dr. Mark Goldsmith, CEO of Revolution, mentioned the overwhelming inquiries from patients and how quickly clinical trial slots fill up. “The demand for daraxonrasib has been extremely high, and it only increases as we release more data,” he explained. The drug targets a mutated protein called KRAS, which is instrumental in many pancreatic, lung, and colon cancers. Developing such a targeted treatment was long seen as a significant challenge.

Moreover, Revolution is testing additional drugs that act similarly to daraxonrasib, but the influx of patient requests has overwhelmed the available spaces for trials.

“There’s a huge waiting list,” Dr. Nilofer Azad from Johns Hopkins Medicine remarked, adding that people often travel considerable distances just to consult with specialists.

The rising interest in daraxonrasib has intensified patient urgency. For instance, Raven Zachary, newly diagnosed with metastatic pancreatic cancer, came prepared to ask critical questions about the drug’s availability at his initial oncologist meeting.

Discussions with patients and families reveal a clear understanding that while daraxonrasib may not guarantee a cure, it represents a chance for more time with loved ones or some freedom from frequent chemotherapy sessions. They expressed a willingness to accept the risks, even acknowledging the possibility of the drug not meeting expectations.

“Every month of delay means more chemotherapy for me,” stated Dr. Ronald Silvestri, a retired pulmonologist battling metastatic pancreatic cancer who has already undergone 32 rounds of treatment.

Historical Context of Drug Access

Efforts to grant desperate patients access to unapproved medications have been ongoing for decades, often leading to debates on the speed and fairness of drug availability. The modern framework for these access programs took shape in the 1980s, driven largely by AIDS patients seeking urgent treatments.

In recent years, similar efforts emerged from patients seeking experimental drugs for conditions like A.L.S. One notable case involved a patient who received a medication through expanded access just days before passing away and long before it was officially approved.

The situation surrounding daraxonrasib reflects many critical factors—an aggressive disease, a lack of effective treatments, and promising clinical data—that suggest a compelling case for establishing a comprehensive expanded access program.

However, the FDA’s authorization applies only within the U.S., necessitating requests through licensed American doctors, which currently restricts many hopeful patients from other countries from accessing this potentially life-saving treatment.

One such patient, Cynthia Ataefe from Buenos Aires, is gravely ill and unable to travel for trials. Her daughter hopes expanded access might offer a solution, stating, “I still hope that somehow we will get the drug in time.”